Geneesmiddelen | Horizonscan geneesmiddelen

autologous anti-CD19-transduced CD3+ cells ^IND

Gilteritinib Glasdegib Guadecitabine Idasanutlin Imetelstat Iomab-B

Ivosidenib

Relapsed or refractory isocitrate dehydrogenase-1 (IDH-1) mutation-positive acute myeloid leukaemia Acute myeloid leukaemia (AML), isocitrate dehydrogenase-1 (IDH1) mutation - first-line combination therapy. ^IND

Luspatercept Sapacitabine Venetoclax ^IND

Brentuximab vedotin ^IND Lisocabtagene maraleucel Polatuzumab vedotin Rituximab ^IND Tafasitamab Tagraxofusp Zanubrutinib

Atezolizumab

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC), after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%. ^IND Adjuvant treatment after surgical resection of high-risk muscle-invasive bladder cancer (MIBC). ^IND

Avelumab ^IND Durvalumab ^IND Enfortumab vedotin Oportuzumab monatox Pembrolizumab ^IND Ramucirumab ^IND Tremelimumab ^IND

Asunercept Autologous glioma tumor cell lysates Brain cancer vaccine Tasadenoturev Vocimagene amiretrorepvec

Abemaciclib ^IND Alpelisib

Atezolizumab

Neoadjuvant treatment for patients with early TNBC in combination with nab-paclitaxel. ^IND Treatment of patients with previously untreated metastatic TNBC in combination with paclitaxel. ^IND

Margetuximab Neratinib ^IND Olaparib ^IND Paclitaxel

Palbociclib

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery. ^IND Patients with HR+/HER2- invasive early breast cancer in combination with standard adjuvant endocrine therapy. ^IND

Pembrolizumab

Breast cancer, metastatic, triple negative, 1L. ^IND Tripple Negative Breast Cancer - Neoadjuvant and adjuvant. ^IND

Pertuzumab / trastuzumab Sacituzumab govitecan

Trastuzumab deruxtecan

Treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 therapies. Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy ^IND Treatment of adult patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane 2L. ^IND

Trastuzumab duocarmazine

Trastuzumab emtansine

Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. ^IND Trastuzumab entansine in combination with pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. ^IND

Tucatinib Veliparib

Acalabrutinib

Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Duvelisib

Ibrutinib

Extension of indication to the existing chronic lymphocytic leukaemia (CLL) indication to include combination use with obinutuzumab for the treatment of adult patients with previously untreated CLL. ^IND Extension of indication in chronic lymphocytic leukaemia (CLL) to add combination with rituximab as follows; Ibrutinib in combination with rituximab or obinutuzumab for the treatment of adult patients with previously untreated CLL (Young and Fit). ^IND

ibrutinib ^IND Moxetumomab pasudotox Ublituximab Venetoclax ^IND

Eflornithine / sulindac Encorafenib ^IND Tegafur / gimeracil / oteraci ^IND

Afatinib ^IND Brilacidin

Durvalumab

Squamous cell carcinoma of the head and neck, 1L PDL 1 in combination with tremelimumab ^IND Squamous cell carcinoma of the head and neck, 1L PDL 1. ^IND

Leukocyte interleukin Pembrolizumab ^IND

Carmustine ^G

Pembrolizumab ^IND

Axicabtagene ciloleucel ^IND Copanlisib

Ibrutinib

Follicular lymphoma (FL), relapsed / refractory. ^IND Marginal zone lymphoma (MZL), relapsed / refractory. ^IND

Umbralisib

Avelumab ^IND Cabozantinib ^IND Ipilimumab ^IND

Pembrolizumab

Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy. ^IND Advanced Renal Cell Carcinoma (1L) in combination with lenvatinib. ^IND

Tivozanib ^IND

Asciminib

Atezolizumab ^IND Pembrolizumab ^IND Pemigatinib

Amivantimab

Atezolizumab

For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy. ^IND Extension of indication to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express PD-L1. ^IND

Avelumab ^IND

Brigatinib

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. ^IND Geïndiceerd voor gebruik als monotherapie voor de behandeling van volwassen patiënten met ALK‑positief (anaplastisch lymfoom kinase) gevorderd niet‑kleincellig longcarcinoom (NSCLC) die eerder zijn behandeld met alectinib. ^IND

Canakinumab ^IND Cemiplimab ^IND Dacomitinib

Durvalumab

Non-small cell lung cancer (NSCLC) stage IV, in combination with tremelimumab and chemo,1L. Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND Imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND

Entrectinib Lurbinectedin Mobocertinib

Nivolumab

Extension of Indication to include first-line treatment of adult patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC) in combination with ipilimumab and two cycles of chemotherapy. ^IND Opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation. ^IND

Osimertinib ^IND

Pembrolizumab

Extension of Indication to include 1st line treatment of locally advanced or metastatic non-small cell lung cancer tumours expressing PD-L1 with a ≥ 1% tumour proportion score (TPS). ^IND Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the treatmen of extensive stage Small Cell Lung Cancer (SCLC) (1L). ^IND

Pralsetinib Selpercatinib Sotorasib Tepotinib Trilaciclib

Nivolumab ^IND

Belantamab mafodotin Carfilzomib ^IND

Daratumumab

Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). ^IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). ^IND Amyloidose eerstelijnsbehandeling in combinatie met bortezomib, cyclofosfamide en dexamethason. ^IND In combinatie met pomalidomide en dexamethason voor patiënten met multipel myeloom die tenminste een eerdere lijn van behandeling hebben gehad. ^IND Subcutaneous formulation indicates for Relapsed or Refractory Multiple Myeloma. ^IND Multipel myeloom frontline behandeling i.c.m. VRd voor patiënten die niet in aanmerking komen voor een ASCT. ^IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die in aanmerking komen voor een ASCT. ^IND Multipel myeloom frontline onderhoudsbehandeling na DVTd, voor patiënten die in aanmerking komen voor een ASCT. ^IND Smouldering multipel myeloom. ^IND

Ibrutinib ^IND Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy. Combinatie van isatuximab met carfilzomib en dexamethason bij patiënten met gerecidiveerd en refractair multipel myeloom na 1 tot maximaal 3 eerdere behandellijnen. ^IND

JNJ-4528 Lenalidomide ^IND Pomalidomide ^IND Selinexor Zanubrutinib

Fedratinib Ropeginterferon alfa-2b

Selumetinib Surufatinib

131I-omburtamab Dostarlimab Entrectinib Glucarpidase Ivosidenib ^IND Larotrectinib Lipegfilgrastim ^IND Nivolumab ^IND

Pembrolizumab

Extension of indication to include first-line treatment of unresectable or metastatic microsatellite instability-high (MSI H) or mismatch repair deficient (dMMR) colorectal cancer in adults for Keytruda. ^IND Advanced Endometrial Cancer (2L+) in combination with lenvatinib. ^IND Locally advanced or metastatic esophageal carcinoma (1L) ^IND Women With Persistent, Recurrent, or Metastatic Cervical Cancer (1L). ^IND

Pexidartinib Sodium thiosulfate

Atezolizumab ^IND Niraparib ^IND Olaparib ^IND Veliparib

Eryaspase (Asparaginase) Olaparib ^IND

Abiraterone

Abiraterone / apalutamide Apalutamide ^IND Cabazitaxel ^G

Darolutamide

Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. ^IND

DCVAC

Enzalutamide

Adult men with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. ^IND De behandeling van volwassen mannen met niet-gemetastaseerd hoog risico-CRPC (castratieresistent prostaatcarcinoom). ^IND

Niraparib ^IND Olaparib ^IND Relugolix

Atezolizumab ^IND

Cemiplimab

Monotherapy treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Libtayo wordt onderzocht in patiënten met gevorderd basaalcelcarcinoom van de huid (cBCC) die progressie vertonen onder behandeling met hedgehog inhibitor therapie of intolerant waren voor eerdere behandeling met hedgehog inhibitor therapie. ^IND

Dabrafenib / Trametinib ^IND Darleukin fibromun Lifileucel Relatlimab Seviprotimut-L Spartalizumab Tavokinogene telseplasmid

autologous anti-CD19-transduced CD3+ cells Axicabtagene ciloleucel ^IND BL-8040 Ibrutinib ^IND Inolimomab Itacitinib Narsoplimab Omidubicel Remestemcel-L Rimiducid Rivogenlecleucel Ruxolitinib ^IND Tabelecleucel Thiotepa ^G

Avapritinib Masitinib Ripretinib Rivoceranib Trastuzumab deruxtecan ^IND

Selpercatinib

Patients With RET-Mutant Medullary Thyroid Cancer. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.

Oncology and Hematology

ALL

Blinatumomab

Dasatinib

AML / MDS

Arseentrioxide

Azacitidine

Ivosidenib

Aggressive non-Hodgkin's lymphoma

Bladder cancer

Atezolizumab

Brain cancer

Breast cancer

Atezolizumab

Palbociclib

Pembrolizumab

Trastuzumab deruxtecan

Trastuzumab emtansine

CLL

Acalabrutinib

Ibrutinib

Colon cancer

Head and neck cancer

Durvalumab

Hematology other

Hodgkin's lymphoma

Indolent non-Hodgkin's lymphoma

Ibrutinib

Kidney cancer

Pembrolizumab

Leukemia

Liver cancer

Lung cancer

Atezolizumab

Brigatinib

Durvalumab

Nivolumab

Pembrolizumab

Mesothelioma

Multiple Myeloma

Daratumumab

Isatuximab

Myeloproliferative disorders

Neuroendocrine cancer

Other oncology

Pembrolizumab

Ovarian cancer

Pancreatic cancer

Prostate cancer

Abiraterone

Darolutamide

Enzalutamide

Skin cancer

Cemiplimab

Stem cell transplants

Stomach cancer

Thyroid cancer

Selpercatinib

Service

About this site